Belgium Liver Diseases Therapeutics Market Report 2022 to 2030

Belgium Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Belgium liver disease therapeutics market will reach a value of $79 Mn from $51 Mn in 2022, growing at a CAGR of 5.7 % during 2022-30. Liver disease therapeutics in Belgium is dominated by a few domestic pharmaceutical companies such as Ablynx, UCB Pharma, and Galapagos. The Liver Disease Therapeutics market in Belgium is segmented into different types of disease and different therapy types. Some of the major factors affecting the Belgium liver disease therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10BEPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Vishwa Modhia

Buy Now

Belgium Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Belgium liver disease therapeutics market will reach a value of $79 Mn from $51 Mn in 2022, growing at a CAGR of 5.7 % during 2022-2030.

Belgium is a high-income, developed country in Western Europe that borders the North Sea. In Belgium, liver disease is a major public health concern, with the alcohol-related liver disease being one of the biggest causes. In Belgium, the prevalence of chronic hepatitis B and C is estimated to be around 0.3 % and 0.5 %, respectively. Non-alcoholic fatty liver disease (NAFLD) is also becoming more common in Belgium as obesity and diabetes rates rise.

According to the latest WHO data published in 2020 liver disease deaths in Belgium reached 1,433 or 1.55% of total deaths. The age-adjusted death rate is 7.38 per 100,000 population ranks Belgium #149 in the world. Belgium, a minor European country, has one of the best healthcare systems in Europe, consistently placing among the top ten European countries with the best healthcare for numerous years. Belgium similarly spends a significant portion of its GDP on healthcare, with only 2.4 % of the population reporting an unmet need for medical care. Belgium's government spent 11.1 % of its GDP on healthcare in 2020.

belgium liver disease therapeutics market analysis

Market Dynamics

Market Growth Drivers

Belgium's healthcare infrastructure is well-developed, with advanced diagnostic and therapeutic facilities available. This has resulted in advances in the diagnosis of liver disease, allowing for earlier detection and treatment. Belgium is strategically located between the United Kingdom, Germany, and France in terms of commerce. Because of vocational education and multilingualism, it also boasts a well-trained workforce. These aspects could boost Belgium's Liver Disease Therapeutics market.

Market Restraints

However, there is a need for more knowledge and education regarding the prevention and management of liver disease, particularly in relation to lifestyle changes such as lowering alcohol intake and promoting healthy diets. According to a study published in the journal Acta Gastroenterologica Belgica, the liver disease kills around 4,000 people in Belgium each year. Belgium has a high level of structural unemployment, and political and financial conflicts exist between Flanders and Wallonia. These factors may deter new entrants into the Belgium Liver Disease Therapeutics market.

Competitive Landscape

Key Players

Galapagos NV: Galapagos NV is a Belgian biotechnology company that produces a range of therapeutics, including those for liver disease
UCB Pharma: UCB Pharma is a multinational pharmaceutical company with a significant presence in Belgium. The company produces a range of therapeutics, including those for liver disease
Ablynx: Ablynx is a Belgian biotechnology company that produces a range of therapeutics, including those for liver disease
KitoZyme: KitoZyme is a Belgian biotechnology company that produces a range of therapeutics, including those for liver disease. Its liver disease products include HepCell, a medication used to treat liver disease caused by viral infections or toxic agents

Healthcare Policies and Reimbursement Scenarios

In Belgium, the regulation of liver disease therapeutics is overseen by the Federal Agency for Medicines and Health Products (FAMHP), which is responsible for ensuring that all pharmaceutical products, including liver disease therapeutics, meet safety, efficacy, and quality standards. To be approved for use in Belgium, liver disease therapeutics must be registered with the FAMHP, and manufacturers must comply with Good Manufacturing Practices (GMP) and other regulatory requirements. In terms of reimbursement, the National Institute for Health, and Disability Insurance (INAMI/RIZIV) is responsible for providing health insurance coverage to Belgian citizens.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Belgium Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.